Bempedoic Acid in Patients with Dyslipidemia: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis are conducted to synthesize the efficacy and safety of bempedoic acid in patients requiring lipid-lowering therapy. PubMed, Embase, and Scopus databases were searched for randomized controlled trials from inception till June 2023. The primary outcome was the...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-05-01
|
| Series: | Medical Journal of Dr. D.Y. Patil Vidyapeeth |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/mjdrdypu.mjdrdypu_576_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | This systematic review and meta-analysis are conducted to synthesize the efficacy and safety of bempedoic acid in patients requiring lipid-lowering therapy. PubMed, Embase, and Scopus databases were searched for randomized controlled trials from inception till June 2023. The primary outcome was the change in the serum lipid profile. The secondary outcomes were the risks of major adverse cardiovascular events, all-cause mortality, hyperuricemia, and myalgia. We pooled mean differences or relative risks (RR) along with 95% confidence intervals (randomeffects model). Five-hundred and thirty-one studies were screened and 17 (n = 21,131) were included for review. There was a significant reduction in the risk of major adverse cardiovascular events (MACE) [RR, 0.88 (95% CI: 0.77 to 0.99), P = 0.03)] and all-cause mortality [RR, 0.90 (95% CI: 0.82 to 0.98), P = 0.02] following bempedoic acid treatment. Treatment with bempedoic acid led to a significant reduction in the mean serum total cholesterol [−34.41 mg/dl (95% CI: −42.43 to −26.39), P < 0.001], low-density lipoprotein cholesterol (LDL-C) [ −33.91 mg/dl (95% CI: −39.66 to −28.17), P < 0.001], and high-density lipoprotein cholesterol (HDL-C) [ −2.40 mg/dl (95% CI: −3.09 to −1.71), P < 0.001] levels. However, there was no significant increase in the risk of hyperuricemia or myalgia following bempedoic acid treatment. The GRADE of evidence was moderate for all outcomes. Bempedoic acid lowers serum total cholesterol and LDL-C levels, reduces the risk of MACE, and has a favorable safety profile. |
|---|---|
| ISSN: | 2589-8302 2589-8310 |